In this final conversation, the Surfers are joined by Veronica Miller to discuss the recent FDA workshop for NIT development. Veronica discusses her unique impressions on the workshop and steers the group to consider the question of “why are we validating a surrogate with a surrogate?”
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. This discussion largely focuses on ideas around distinguishing the difference between NITs to qualify patients for trials versus to evaluate efficacy of drugs.
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. The group discusses loss aversion, screen fail rates, the future of FDA decision making and more.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.
The Surfers are joined by Naim Alkhouri, Laurent Castera and Veronica Miller in three distinct interviews on the topic of the recent FDA workshop around NIT development and the future of the field.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating final conversation which raises new and interesting topics covered at the event.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. In this conversation, presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green to ask and answer questions surrounding the task of testing patients for optimized results under different scenarios.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.
